Liraglutide (Saxenda): What It Is: GLP-1 receptor agonist (same class as semaglutide) Older, less effective version Daily injection required Effectiveness: Average Weight Loss: 5-8% of body weight SCALE Trial: 8% loss vs 2.6% placebo Significantly less effective than semaglutide (daily) or tirzepatide Why Less Effective: Shorter half-life requires daily dosing Less consistent drug levels Lower peak concentrations Side Effects: Similar to semaglutide (nausea, diarrhea, constipation) Same GLP-1 class warnings Cost: $1,400/month More expensive than newer, more effective options Who Should Consider: Almost no one Semaglutide and tirzepatide have largely replaced liraglutide Rarely prescribed for weight loss anymore Comparison Table: All FDA-Approved Weight Loss Medications: Bottom Line on Non-GLP-1 Options: For most patients seeking effective weight loss: Best Results: Tirzepatide or semaglutide If GLP-1s Contraindicated: Phentermine-topiramate Avoid: Orlistat, naltrexone-bupropion (poor effectiveness) Short-term Only: Phentermine The GLP-1 revolution has made older medications largely obsolete for patients who can tolerate them

requires close monitoring Individual responses vary considerably, and some patients with IBS report minimal additional digestive symptoms, while others find the side effects intolerable
Developer strategy : Both are Novo Nordisk programs, suggesting the company views them as complementary rather than competing -- CagriSema as the nearer-term injectable option, amycretin as the longer-term oral strategy
While it can be effective, ongoing administration without breaks might reduce its effectiveness over time 1
The ease of weekly shots makes maintaining treatment effortless